Aegle Therapeutics
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
400 Tradecenter Ste 5900, Woburn, Massac...Phone Number
(954) 736-6682Website
www.aegletherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Aegle Therapeutics
AEGLE Therapeutics Corporation is a privately held, clinical-stage biotechnology company headquartered in Woburn, Massachusetts, founded in 2013. The company is a pioneer in regenerative medicine, developing first-in-class extracellular vesicle (EV) therapies derived from allogeneic bone marrow-derived mesenchymal stem cells (MSCs) to treat rare and serious diseases with significant unmet medical needs. AEGLE's patented EV harvesting and isolation technology, exclusively licensed from the University of Miami, enables the gentle isolation of native EVs from MSCs without damaging or modifying them. These cell-free EVs carry complex biological payloads including proteins, nucleic acids, and immunomodulatory agents that promote regenerative healing, reduce inflammation, and modulate the immune system in recipient cells. The company's lead therapeutic candidate, AGLE-102, is being developed to treat dystrophic epidermolysis bullosa (DEB), a rare and severe genetic pediatric skin blisteringRead more
Aegle Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aegle Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Aegle Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Aegle Therapeutics has new funding data
Check out if Aegle Therapeutics is spiking on competitors!
Click to see if Aegle Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Aegle Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Aegle Therapeutics
Earning: See what the market has to say on Aegle Therapeutics recently announced quarterly report
Aegle Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Aegle Therapeutics
Compare insights from companies similar to Aegle Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aegle Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aegle Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aegle Therapeutics.
Aegle Therapeutics financials insights
Gather financial insights about Aegle Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$4M
Series A
$6.5M
2026
Debt
$456K
Aegle Therapeutics Tech Stack
A closer look at the technologies used by Aegle Therapeutics
Most Recent Scoops
Funding
Funding
Executive Move
Executive Moves, Board of Directors
Funding
Funding
Funding
Aegle Therapeutics News & Media
Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Trial of AGLE-102™ in Patients with Dystrophic Epidermolysis Bullosa ("DEB")
AGLE-102 is a novel extracellular vesicle therapy being developed for the treatment of rare and immuno-dermatological disorders. WOBURN, Mass., Aug. 14, 2024 /PRNewswire/ -- Aegle Therapeutics Corp., a clinical-stage biopharmaceutical company developing novel extracellular vesicle ("EV")...Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle Therapy
Phase 1/2a clinical trial will evaluate the safety and efficacy of administering AGLE-102™ to treat severe second-degree burns AGLE-102™ is being developed for the treatment of severe dermatological and immune based disorders WOBURN, Mass., Aug. 16, 2023 /PRNewswire/ -- Aegle Therapeutics...Aegle Therapeutics Announces Award of Grant by U.S. Department of Defense's ("DoD") Congressionally Directed Medical Research Programs ("CDMRP") for Development of AGLE-102
BOSTON and MIAMI, Oct. 8, 2020 /PRNewswire/ -- Aegle Therapeutics Corporation, a first-in-class biotechnology company developing extracellular vesicles as therapy, today announced that the Company has been awarded a grant by the U.S. DoD's CDMRP to fund the continued development of the...Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa
BOSTON and MIAMI, Oct. 6, 2020 /PRNewswire/ -- Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD)...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Aegle Therapeutics
Sign Up For FreeTo access detailed company insights
AEGLE Therapeutics Corporation is a privately held, clinical-stage biotechnology company headquartered in Woburn, Massachusetts, founded in 2013. The company is a pioneer in regenerative medicine, developing first-in-class extracellular vesicle (EV) therapies derived from allogeneic bone marrow-derived mesenchymal stem cells (MSCs) to treat rare an... Read More
